The Clinical Evolution of Diffuse Myocardial Fibrosis in Patients With Arterial Hypertension and Heart Failure With Mildly Reduced Ejection Fraction Treated by Olmesartan or Sacubitril / Valsartan
Authors:
- L. V. ShulzhenkoLSL. V. Shulzhenko
- T. A. BatyralievTBT. A. Batyraliev
- Z. A. KarbenZKZ. A. Karben
- O. V. GurovichOGO. V. Gurovich
- D. V. FettserDFD. V. Fettser
- T. N. KuznetsovaTKT. N. Kuznetsova
- E. Yu. IvanenkovaEIE. Yu. Ivanenkova
- B. A. AkbalaevaBAB. A. Akbalaeva
- N. Rayimbek UuluNUN. Rayimbek Uulu
- S. ToygonbaevSTS. Toygonbaev
- A. T. MansharipovaAMA. T. Mansharipova
Open Access
- 26 December 2023
- journal article
- research article
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 63 (12) , 31-38
Abstract
Aim A 12-month evaluation of the potentialities of the angiotensin II receptor inhibitor olmesartan (Olme) and the angiotensin receptor and neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with arterial hypertension (AH) and dyslipidemia in the dynamics of the following indicators of chronic heart failure (CHF): N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), LV global longitudinal strain (LV GLS) in diffuse myocardial fibrosis (MF) previously diagnosed by magnetic resonance imaging (MRI). Material and methods Olmesartan medoxomil (n=56) and sacubitril/valsartan (n=63) were used for 12 months in patients with hypertension, dyslipidemia and NYHA functional class II-III CHF with mid-range LVEF (CHFmrEF). MF was diagnosed by the following MRI criteria: late gadolinium enhancement and an increased proportion of extracellular matrix (33% or more). The frequency of persisting late gadolinium enhancement and the increased proportion of extracellular matrix (33% or more) was evaluated at 12 months; changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), NT-proBNP, and LV GLS were evaluated after 3, 6, and 12 months of follow-up. Results Baseline parameters did not differ between groups. The late gadolinium enhancement and increased proportion of extracellular matrix were present at baseline in all patients of both groups (100%; p=1.0). Already at 3 months, statistically significant decreases in SBP and DBP were observed in both groups. In addition, the LV GLS monitoring showed LV GLS significantly increased in both groups after 3 months and continued changing after 6 and 12 months. The NT-proBNP concentration significantly decreased in both groups already after 3 months and continued to decrease after 6 and 12 months. At 6 and 12 months, sacubitril/valsartan was superior to olmesartan in reducing SBP and NT-proBNP and in restoring LV GLS. At 12 months, the incidence of persisting, abnormal late gadolinium enhancement and increased proportion of extracellular matrix was significantly less in the ARNI group. Conclusion Olmesartan was demonstrated effective in the multi-modality therapy of CHFmrEF and MF in patients with AH and dyslipidemia. ARNI was superior to olmesartan in this regard, but further research of this issue is required.Keywords
This publication has 22 references indexed in Scilit:
- Myocardial Tissue Characterization and Fibrosis by ImagingJACC: Cardiovascular Imaging, 2020
- Myocardial Interstitial Fibrosis in Heart FailureJACC, 2018
- Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double‐blind, 8‐week studyThe Journal of Clinical Hypertension, 2018
- CMR–Derived Extracellular Volume Fraction as a Marker for Myocardial FibrosisJACC: Cardiovascular Imaging, 2018
- Heart repair by reprogramming non-myocytes with cardiac transcription factorsNature, 2012
- Spironolactone Therapy is Associated with Reduced Ventricular Tachycardia Rate in Patients with CardiomyopathyPacing and Clinical Electrophysiology, 2010
- Cardiac Magnetic Resonance Monitors Reversible and Irreversible Myocardial Injury in MyocarditisJACC: Cardiovascular Imaging, 2009
- Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and FunctionPhysiological Reviews, 2007
- Additive effects of combined blockade of AT1receptor and HMG-CoA reductase on left ventricular remodeling in infarcted ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive PatientsCirculation, 2002